Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of P128 for Nasal S. aureus Carriage
NCT01746654Phase 2Completed
- Sponsor
- GangaGen
- Start
- Dec 2012
- Primary completion
- Oct 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of P128 in Staphylococcus aureus nasal colonization (4 arms), sponsored by GangaGen. Primary endpoints: Safety and tolerability at 7 Days and Efficacy at 7 Days. Started Dec 2012; status: completed.
02
Drugs
P128
03
Conditions
Staphylococcus aureus nasal colonization
Beyond the preview
Go deeper on NCT01746654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746654.